ArticleFrontiers in pharmacology2026

PCSK9 inhibitor use and risk of dementia and neurodegenerative diseases in adults aged 50 Years and older: a global electronic health record study.

Shuo-Yan Gau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.